190 related articles for article (PubMed ID: 35152722)
21. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
22. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
23. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
[TBL] [Abstract][Full Text] [Related]
24. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
[TBL] [Abstract][Full Text] [Related]
26. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
27. Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation.
Vaidya A; Doherty E; Wu X; Huang S; Hebbar N; Thanekar U; Bonifant CL; Cheng C; Gottschalk S; Velasquez MP
Haematologica; 2023 Apr; 108(4):1039-1052. PubMed ID: 35899386
[TBL] [Abstract][Full Text] [Related]
28. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
29. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
30. Vγ9Vδ2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth.
Zhang X; Ng YY; Du Z; Li Z; Chen C; Xiao L; Chng WJ; Wang S
PLoS One; 2022; 17(6):e0267475. PubMed ID: 35709135
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
32. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
33. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
Lynn RC; Poussin M; Kalota A; Feng Y; Low PS; Dimitrov DS; Powell DJ
Blood; 2015 May; 125(22):3466-76. PubMed ID: 25887778
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
[TBL] [Abstract][Full Text] [Related]
35. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML; Sanchez Martinez D; Gutierrez Aguera F; Roca Ho H; Castella M; Zanetti SR; Velasco Hernandez T; Diaz de la Guardia R; Castaño J; Anguita E; Vives S; Nomdedeu J; Lapillone H; Bras AE; van der Velden VHJ; Junca J; Marin P; Bataller A; Esteve J; Vick B; Jeremias I; Lopez A; Sorigue M; Bueno C; Menendez P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
[TBL] [Abstract][Full Text] [Related]
36. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
37. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
38. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
[TBL] [Abstract][Full Text] [Related]
40. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]